-
Company Insights
New![]()
Innovation and Patenting activity of Giant Manufacturing Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Giant Manufacturing Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
New![]()
Innovation and Patenting activity of Giant Network Group Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Giant Network Group Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABSK-021 in Tenosynovial Giant Cell Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ABSK-021 in Tenosynovial Giant Cell Tumor Drug Details: ABSK-021 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LN-145 in Giant Cell Tumor Of Bone
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LN-145 in Giant Cell Tumor Of Bone Drug Details: Lifileucel (LN-145) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Emactuzumab in Tenosynovial Giant Cell Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Emactuzumab in Tenosynovial Giant Cell Tumor Drug Details:Emactuzumab (RG-7155, RO5509554) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nilotinib in Tenosynovial Giant Cell Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nilotinib in Tenosynovial Giant Cell Tumor Drug Details: Nilotinib (Tasigna, AMN107) is a signal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vimseltinib in Tenosynovial Giant Cell Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vimseltinib in Tenosynovial Giant Cell Tumor Drug Details: Vimseltinib (DCC-3014) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LY-01011 in Giant Cell Tumor Of Bone
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LY-01011 in Giant Cell Tumor Of Bone Drug Details: Denosumab biosimilar (LY-01011) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HMPL-760 in Tenosynovial Giant Cell Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HMPL-760 in Tenosynovial Giant Cell Tumor Drug Details:HMPL-760 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Giant Cell Tumor Of Bone
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Denosumab Biosimilar in Giant Cell Tumor Of BoneDrug Details:Denosumab (JHL-1266) is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.